Immediate Impact
50 standout
Citing Papers
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 Standout
Nitric oxide signaling in health and disease
2022 Standout
Works of P. V. Colthup being referenced
GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain
2005
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| P. V. Colthup | 44 | 153 | 138 | 90 | 9 | 480 | |
| L. E. Martin | 66 | 99 | 68 | 90 | 11 | 488 | |
| R. Hendriks | 31 | 63 | 110 | 98 | 14 | 573 | |
| Robert F. Butz | 16 | 114 | 55 | 96 | 20 | 495 | |
| N. Michiels | 9 | 116 | 205 | 65 | 10 | 483 | |
| Seiu Îda | 8 | 257 | 60 | 133 | 7 | 525 | |
| Osamu Kamata | 8 | 189 | 48 | 159 | 20 | 505 | |
| J. A. Watt | 11 | 223 | 60 | 63 | 19 | 539 | |
| Keith McCormack | 7 | 232 | 187 | 52 | 11 | 535 | |
| Ruth R. Levine | 6 | 81 | 56 | 105 | 22 | 495 | |
| Gregor Vetter | 4 | 172 | 96 | 108 | 14 | 554 |
All Works
Loading papers...